Targeted Metabolomics

The Metabolomics Core has established a large number of targeted panels for quantitation of selected groups of metabolites using mass spectrometry. The key distinction between untargeted and targeted measurements is that these targeted panels provide accurate absolute quantitation of a focused group of analytes using available standards.

Targeted metabolomics is a quantitative approach in which a known set of metabolites is quantitated using 13C or 15N isotope-labeled internal or external reference compounds. The resulting data can then be used as input variables for statistical analysis.

The Metabolomics Core's panels include many metabolites of intermediary metabolism, lipids, carboxylic acids, organic acids, neuromodulators and drug metabolites. These types of panels are established to meet the needs of investigators on a case-by-case basis. Investigators who are interested in measuring metabolites not listed below should contact the core director to discuss possibilities for establishing a method. Contact the lab.

The following panels are currently established and available:

Amino compounds

Histidine

Glutamine

alpha-Aminoadipic acid

Tyrosine

Hydroxyproline

Ethanolamine

beta-Aminoisobutyric acid

Methionine

1-Methylhistidine

Glycine

Proline

Valine

3-Methylhistidine

Aspartic Acid

Hydroxylysine 1

n-Valine

Asparagine

Sarcosine

Hydroxylysine 2

Isoleucine

Phosphoethanolamine

Citrulline

alpha-Amino-n-butyric acid

allo-Isoleucine

Arginine

Glutamic Acid

Ornithine

Leucine

Carnosine

beta-Alanine

Cystathionine 1

Homocystine

Taurine

Threonine

Cystathionine 2

Phenylalanine

Anserine

Alanine

Cystine

Tryptophan

Serine

gamma-Amino-n-butyric acid

Lysine

Neurotransmitters

gamma-Aminobutyric acid

Aspartic acid

Glutamic acid

Norepinephrine

Acetylcholine

Dopamine

Glycine

Serotonin

Adenosine

D-serine

Histidine

Taurine

Tricarboxylic acids

Lactic acid

Oxaloacetic acid

Cis-Aconitic acid

Glutamic acid

Fumaric acid

Ketoglutaric acid

Citric acid

Isocitric acid

Succinic acid

Malic acid

2-Hydroxyglutaric acid

Aspartic acid

Fatty acids

Octanoic acid

Palmitelaidic acid

Linoleic acid

Docosahexaenoic acid

Myristic acid

Stearic acid

alpha-Linolenic acid

Palmitic acid

Oleic acid

Arachidonic acid

Palmitoleic acid

Elaidic acid

Eicosapentaenoic acid

Short-chain fatty acids

Acetic acid

Propionic acid

Isobutyric acid

Butyric acid

Valeric acid

Isovaleric acid

Hexanoic acid

Sphingolipids

Sphingosine

C8-Ceramide

C18:1-Ceramide

C22-Ceramide

Sphinganine

C14-Ceramide

C18-Ceramide

C24:1-Ceramide

Sphingosine-1-phosphate

C16-Ceramide

C20-Ceramide

C24-Ceramide

Hexosylceramides

HexCer-Sph

HexCer-C18:1

HexCer-C14

HexCer-C24

HexCer-C12

HexCer-C18

HexCer-C20

HexCer-C16

HexCer-C24:1

HexCer-C22

Diacylglycerols

Dilinoleoyl-glycerol

Palmitoyl-linoleoyl-glycerol

Dipalmitoyl-glycerol

Palmitoyl-oleoyl-glycerol

Stearoyl-linoleoyl-glycerol

Dioleoyl-glycerol

Stearoly-oleoyl-glycerol

 

Acylcarnitines

Carnitine

Butyrylcarnitine

Lauroylcarnitine

Linoleoylcarnitine

Acetylcarnitine

Isovalerylcarnitine

Myristoylcarnitine

Oleoylcarnitine

Propionylcarnitine

Octanoylcarnitine

Palmitoylcarnitine

Stearoylcarnitine

Fatty acyl CoAs

malonyl CoA

C14-CoA

C16-CoA

C16:1-CoA

C18-CoA

C18:1-CoA

C18:2-CoA

C20-CoA

Trimethylamine compounds

carnitine

trimethylamine

trimethylamine-N-oxide

choline

betaine

Drugs and drug metabolites

Metformin

Acamprosate

Valproic acid

Nicardipine

Nimodipine

Oxidative damage

8-Oxo-2'-deoxyguanosine

deoxyguanosine

Acknowledgment

National Institutes of Health (NIH) Public Access Policy requires that all publication that results from NIH funding be uploaded to PubMed Central. Review the process for uploading publications.

All users of the core must cite the Mayo Clinic Metabolomics Resource Core grant as a funding source in any resulting publications. Use this language:

This publication was made possible by Mayo Clinic Metabolomics Resource Core through grant number U24DK100469 from the National Institute of Diabetes and Digestive and Kidney Diseases and originates from the National Institutes of Health Director's Common Fund.